Biodesix (NASDAQ:BDSX) Director Acquires $944,800.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 80,000 shares of the stock in a transaction that occurred on Friday, January 23rd. The stock was purchased at an average price of $11.81 per share, for a total transaction of $944,800.00. Following the completion of the purchase, the director directly owned 1,543,210 shares in the company, valued at $18,225,310.10. The trade was a 5.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Biodesix Stock Down 6.5%

Biodesix stock opened at $9.66 on Friday. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84. Biodesix, Inc. has a fifty-two week low of $3.44 and a fifty-two week high of $21.60. The firm has a fifty day moving average price of $7.88 and a two-hundred day moving average price of $7.76. The firm has a market cap of $76.89 million, a price-to-earnings ratio of -1.74 and a beta of 0.60.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%.The business had revenue of $21.77 million for the quarter, compared to analyst estimates of $20.98 million. As a group, analysts forecast that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BDSX. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Biodesix presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

Institutional Trading of Biodesix

Several institutional investors have recently made changes to their positions in the business. XTX Topco Ltd raised its position in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Biodesix in the 3rd quarter worth approximately $113,000. Oracle Investment Management Inc. acquired a new position in shares of Biodesix in the 3rd quarter worth approximately $113,000. Finally, Aberdeen Group plc bought a new position in shares of Biodesix during the 4th quarter worth approximately $1,784,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.